Allogene Stock Analysis


USD 8.86  0.21  2.32%   

The big decline in price over the last few months for Allogene Therapeutics could raise concerns from institutional investors as the firm is trading at a share price of 8.86 on 637,065 in volume. The company management teams failed to add value to investors and position the firm supply of money to exploit market volatility in November. However, diversifying your holdings with Allogene Therapeutics or similar stocks can still protect your portfolios during high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 4.31. This high volatility is attributed to the latest market swings and not-so-good earnings reports for some of the Allogene Therapeutics partners.
Please continue to Trending Equities.
The Allogene Therapeutics stock analysis report makes it easy to digest most publicly released information about Allogene Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Allogene Stock analysis module also helps to analyze the Allogene Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Allogene Stock Analysis Notes

About 30.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.81. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 2.2. The entity had not issued any dividends in recent years. Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California. Allogene Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 344 people. For more info on Allogene Therapeutics please contact David Chang at 650 457 2700 or go to

Allogene Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Allogene Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Allogene Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Allogene Therapeutics generated a negative expected return over the last 90 days
Allogene Therapeutics has high historical volatility and very poor performance
The company reported the previous year's revenue of 38.49 M. Net Loss for the year was (257 M) with loss before overhead, payroll, taxes, and interest of (181.69 M).
Allogene Therapeutics currently holds about 490.49 M in cash with (184.81 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.41.
Allogene Therapeutics has a frail financial position based on the latest SEC disclosures
Over 76.0% of the company shares are held by institutions such as insurance companies
Latest headline from Cancer stocks languish amid challenging markets - BioWorld Online

Allogene Therapeutics Upcoming and Recent Events

Earnings reports are used by Allogene Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Allogene Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report24th of February 2022
Next Financial Report4th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End24th of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Allogene Largest EPS Surprises

Earnings surprises can significantly impact Allogene Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Allogene Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Allogene Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Allogene Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Allogene Therapeutics specific information freely available to individual and institutional investors to make a timely investment decision.
9th of August 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
20th of July 2022
Unclassified Corporate Event
12th of July 2022
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Unclassified Corporate Event
21st of June 2022
Unclassified Corporate Event
17th of June 2022
Financial Statements and Exhibits. Submission of Matters to a Vote of Security Holders
4th of May 2022
Financial Statements and Exhibits. Results of Operations and Financial Condition
14th of April 2022
Unclassified Corporate Event
7th of April 2022
Unclassified Corporate Event

Allogene Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.36 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Allogene Therapeutics's market, we take the total number of its shares issued and multiply it by Allogene Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Allogene Profitablity

Allogene Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Allogene Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Allogene Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Allogene Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Allogene Therapeutics' profitability requires more research than a typical breakdown of Allogene Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(23.07) (24.89) 
Return on Average Assets(20.41) (22.02) 
Return on Average Equity(23.18) (25.01) 
Return on Invested Capital(0.29) (0.31) 
Return on Sales(6.01) (6.48) 

Management Efficiency

The entity has return on total asset (ROA) of (0.1989) % which means that it has lost $0.1989 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.3657) %, meaning that it created substantial loss on money invested by shareholders. Allogene Therapeutics management efficiency ratios could be used to measure how well allogene therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Investment is estimated to slide to -24.89. The value of Return on Average Assets is estimated to slide to -22.02. Allogene Therapeutics Current Assets are quite stable at the moment as compared to the past year. The company's current value of Current Assets is estimated at 493.22 Million. Goodwill and Intangible Assets is expected to rise to about 139.5 K this year, although the value of Total Assets will most likely fall to about 942.2 M.
Last ReportedProjected for 2022
Book Value per Share 6.75  8.42 
Enterprise Value over EBIT(8.00) (8.63) 
Enterprise Value over EBITDA(8.02) (8.65) 
Price to Book Value 2.32  2.83 
Tangible Assets Book Value per Share 7.65  9.46 
Enterprise ValueB2.3 B
Tangible Asset ValueB1.1 B

Technical Drivers

As of the 6th of December, Allogene Therapeutics shows the risk adjusted performance of (0.18), and Mean Deviation of 3.41. Allogene Therapeutics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to break down and interpolate nineteen technical drivers for Allogene Therapeutics, which can be compared to its rivals. Please confirm Allogene Therapeutics downside deviation, jensen alpha, as well as the relationship between the Jensen Alpha and downside variance to decide if Allogene Therapeutics is priced correctly, providing market reflects its regular price of 8.86 per share. Given that Allogene Therapeutics has jensen alpha of (0.65), we suggest you to validate Allogene Therapeutics's prevailing market performance to make sure the company can sustain itself at a future point.

Allogene Therapeutics Price Movement Analysis

The output start index for this execution was fourty-nine with a total number of output elements of twelve. The Mid-point over period is an average of Allogene Therapeutics highest and lowest values attained during the given period.

Allogene Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Allogene Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Allogene Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Allogene Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amado Rafael over a month ago via Macroaxis 
Payment of 8464 shares by Amado Rafael of Allogene Therapeutics subject to Rule 16b-3
Amado Rafael over two months ago via Macroaxis 
Payment of 8968 shares by Amado Rafael of Allogene Therapeutics subject to Rule 16b-3
Owen Witte over three months ago via Macroaxis 
Sale by Owen Witte of 5000 shares of Allogene Therapeutics
Amado Rafael over three months ago via Macroaxis 
Sale by Amado Rafael of 2000 shares of Allogene Therapeutics
Mayo Stephen over three months ago via Macroaxis 
Acquisition by Mayo Stephen of 54487 shares of Allogene Therapeutics subject to Rule 16b-3
Amado Rafael over three months ago via Macroaxis 
Sale by Amado Rafael of 2000 shares of Allogene Therapeutics
Owen Witte over three months ago via Macroaxis 
Sale by Owen Witte of 10000 shares of Allogene Therapeutics
Amado Rafael over three months ago via Macroaxis 
Sale by Amado Rafael of 2000 shares of Allogene Therapeutics
Barrett Elizabeth A over three months ago via Macroaxis 
Acquisition by Barrett Elizabeth A of 71070 shares of Allogene Therapeutics subject to Rule 16b-3
Pf Equity Holdings 2 Bv over six months ago via Macroaxis 
Acquisition or disposition of Allogene Therapeutics securities by Pf Equity Holdings 2 Bv
Arie Belldegrun over six months ago via Macroaxis 
Acquisition or disposition of Allogene Therapeutics securities by Arie Belldegrun
Arie Belldegrun over six months ago via Macroaxis 
Acquisition or disposition of Allogene Therapeutics securities by Arie Belldegrun

Allogene Therapeutics Predictive Daily Indicators

Allogene Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Allogene Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Allogene Therapeutics Forecast Models

Allogene Therapeutics time-series forecasting models is one of many Allogene Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Allogene Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Allogene Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Allogene Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Allogene shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Allogene Therapeutics. By using and applying Allogene Stock analysis, traders can create a robust methodology for identifying Allogene entry and exit points for their positions.
Last ReportedProjected for 2022
Gross Margin 0.90  0.89 

Current Allogene Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Allogene analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Allogene analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Allogene Therapeutics current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Allogene analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Allogene stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Allogene Therapeutics, talking to its executives and customers, or listening to Allogene conference calls.
Allogene Analyst Advice Details

Allogene Stock Analysis Indicators

Allogene Therapeutics stock analysis indicators help investors evaluate how Allogene Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Allogene Therapeutics shares will generate the highest return on investment. By understating and applying Allogene Therapeutics stock analysis, traders can identify Allogene Therapeutics position entry and exit signals to maximize returns.
Begin Period Cash Flow192800000.00
Logo U R LimglogosUSALLO.png
Common Stock Shares Outstanding120370177.00
Total Stockholder Equity916406000.00
DescriptionAllogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor T cell p
Total Cashflows From Investing Activities163655000.00
Property Plant And Equipment Net181020000.00
Retained Earnings-903348000.00
Cash And Short Term Investments457302000.00
Retained Earnings Total Equity-903348000.00
Accounts Payable10255000.00
Net Debt-103385000.00
50 Day M A10.2216
Total Current Liabilities48174000.00
Currency CodeUSD
Other Operating Expenses294281000.00
Non Current Assets Total567311000.00
Common Stock Total Equity142000.00
Non Currrent Assets Other16107000.00
Please continue to Trending Equities. You can also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for analysis

When running Allogene Therapeutics price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Global Correlations
Find global opportunities by holding instruments from different markets
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Fundamental Analysis
View fundamental data based on most recent published financial statements
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.4 B
Return On Assets
Return On Equity
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Allogene Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.